Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Biosis Healing is a leading Chinese biotechnology company specializing in the development and manufacturing of regenerative medicine materials and surgical implants. The company's core technology centers on non-crosslinked extracellular matrix (ECM) derived from porcine small intestinal submucosa (SIS), which serves as a bioactive scaffold to promote tissue regeneration and remodeling. Their commercial portfolio includes advanced surgical meshes for hernia and dural repair, as well as specialized products for wound care and anorectal surgery. By replacing traditional synthetic materials with degradable biological scaffolds, Biosis Healing aims to reduce complications and improve long-term clinical outcomes in soft tissue reconstruction. The company maintains a robust R&D pipeline focused on expanding the applications of SIS technology across multiple surgical disciplines.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Beijing Biosis Healing Regenerative Medicine.